FDA Severe-Bleeding Workshop Addresses Need For Effective Local Agents
This article was originally published in The Gray Sheet
Executive Summary
Panelists at a recent FDA workshop on severe bleeding said there is a need for effective local agents to treat severe bleeding in trauma and surgical cases, and explored a set of primary clinical endpoints for studying the products in rigorous trials.
You may also be interested in...
New Products In Brief
Recent debuts and approvals include Covidien’s AS Meniscal repair device, Medtronic’s Sentrino continuous glucose management system and Blue Belt’s NavioPFS system for partial knee replacement.
News In Brief
Genzyme unloads Dx unit
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.